Testing ALN-6222 in Adults With Obesity
Tests the drug ALN-6222, given as an injection, in adults with obesity.
Plain-language title generated from the registry record
Registry title: A Study to Evaluate ALN-6222 in Participants With Obesity
Key facts
- Where
- Mount Royal, CanadaSee the site
- Phase
- Phase 1
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 65 years old?
Source: NCT07624071, who can take part
Where in Canada
- Mount RoyalMount Royal, CanadaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Alnylam Pharmaceuticals
- Trial code
- NCT07624071
- Record updated
- 21 October 2026
- Original description
This is a first in human, randomized, double-blind (DB), placebo-controlled, single ascending dose (SAD), Phase 1 study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and efficacy of ALN-6222 administered subcutaneously (SC) in adult participants with obesity.Read full original descriptionShow less
A Phase 1, Randomized, Double-blind, Placebo-controlled Study of the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of ALN-6222 in Adult Participants With Obesity
This is a first in human, randomized, double-blind (DB), placebo-controlled, single ascending dose (SAD), Phase 1 study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and efficacy of ALN-6222 administered subcutaneously (SC) in adult participants with obesity.
Inclusion: Is an adult patient with a body mass index ≥30 kg/m\^2 to <40 kg/m\^2; Has a hemoglobin A1c <6.5%.
Exclusion: Has known human immunodeficiency virus (HIV) infection; or known current or chronic hepatitis C virus or hepatitis B virus infection; Has alanine aminotransferase (ALT) or aspartate aminotransferase (AST) >1.5 times the upper limit of normal (ULN); Has an estimated glomerular filtration (eGFR) of <60 mL/min/1.73m\^2 at screening; Note: other protocol defined inclusion / exclusion criteria apply.